BioMarin Pharmaceutical has licensed three drug candidates to Ascendis Pharma, including TransCon CNP, Navepegritide, and Yuviwel. This deal resolves pending litigation between the two companies and establishes a royalty structure for BioMarin on future sales, indicating a strategic shift in BioMarin's portfolio and a potential revenue stream.
BioMarin Pharmaceutical has entered into a licensing agreement with Ascendis Pharma, granting Ascendis rights to TransCon CNP, Navepegritide, and Yuviwel. This agreement is significant as it not only provides BioMarin with a royalty stream (20% U.S., 18% EU/Br/Sk on sales until May 2030) but also resolves all pending litigation between the two companies. For BioMarin, this could be seen as a strategic move to streamline its pipeline and monetize assets, potentially leading to a more focused R&D effort and a new, albeit indirect, revenue source. For Ascendis, gaining these drug candidates expands its portfolio and could accelerate its market presence in relevant therapeutic areas. The short-term implication is a resolution of legal overhang for both companies, while the long-term impact depends on the commercial success of the licensed products. Traders should consider the potential for future royalty income for BMRN and the development costs and market potential for ASND.